DexCom (NASDAQ:DXCM) Upgraded by UBS Group to Strong-Buy Rating

UBS Group upgraded shares of DexCom (NASDAQ:DXCM) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

DXCM has been the topic of several other reports. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Barclays reiterated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Bank of America decreased their target price on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Deutsche Bank Aktiengesellschaft began coverage on DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target on the stock. Finally, Canaccord Genuity Group set a $82.00 price target on DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.40.

DexCom Trading Up 0.4%

NASDAQ:DXCM opened at $75.14 on Tuesday. DexCom has a one year low of $54.11 and a one year high of $89.98. The business has a fifty day moving average price of $72.86 and a 200-day moving average price of $69.05. The firm has a market capitalization of $28.99 billion, a price-to-earnings ratio of 32.11, a price-to-earnings-growth ratio of 1.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 EPS. Sell-side analysts forecast that DexCom will post 2.57 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,506 shares of company stock worth $7,205,258 over the last three months. 0.28% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently bought and sold shares of DXCM. Tema ETFs LLC grew its stake in shares of DexCom by 14.2% in the 2nd quarter. Tema ETFs LLC now owns 21,664 shares of the medical device company’s stock worth $1,459,000 after buying an additional 2,688 shares in the last quarter. E. Ohman J or Asset Management AB lifted its holdings in shares of DexCom by 18.9% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 113,204 shares of the medical device company’s stock valued at $7,624,000 after acquiring an additional 18,012 shares during the last quarter. Paladin Wealth LLC grew its position in DexCom by 17.4% in the second quarter. Paladin Wealth LLC now owns 9,338 shares of the medical device company’s stock worth $629,000 after acquiring an additional 1,386 shares in the last quarter. Arista Wealth Management LLC bought a new stake in DexCom during the second quarter worth approximately $337,000. Finally, Sax Wealth Advisors LLC raised its position in DexCom by 46.1% during the second quarter. Sax Wealth Advisors LLC now owns 17,001 shares of the medical device company’s stock valued at $1,068,000 after purchasing an additional 5,364 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.